Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTN NASDAQ:EDIT NASDAQ:FULC NASDAQ:KALA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTNHillstream Biopharma$3.35$3.20$1.08▼$9.08$233.85M1.411.09 million shs2.76 million shsEDITEditas Medicine$2.69$2.94$1.66▼$4.54$263.37M2.163.59 million shs3.28 million shsFULCFulcrum Therapeutics$3.70$6.16$2.83▼$15.74$246.54M2.934.58 million shs6.10 million shsKALAKALA BIO$3.61$4.62$2.03▼$1,030.00$67.11M-2.4145,460 shs956,837 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTNHillstream Biopharma0.00%+8.41%0.00%+0.60%+334,999,900.00%EDITEditas Medicine0.00%+7.60%+0.75%+14.96%+14.47%FULCFulcrum Therapeutics0.00%+7.25%-43.85%-45.35%-41.82%KALAKALA BIO0.00%+37.26%+38.85%-69.51%-98.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTNHillstream Biopharma$3.35$3.20$1.08▼$9.08$233.85M1.411.09 million shs2.76 million shsEDITEditas Medicine$2.69$2.94$1.66▼$4.54$263.37M2.163.59 million shs3.28 million shsFULCFulcrum Therapeutics$3.70$6.16$2.83▼$15.74$246.54M2.934.58 million shs6.10 million shsKALAKALA BIO$3.61$4.62$2.03▼$1,030.00$67.11M-2.4145,460 shs956,837 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTNHillstream Biopharma0.00%+8.41%0.00%+0.60%+334,999,900.00%EDITEditas Medicine0.00%+7.60%+0.75%+14.96%+14.47%FULCFulcrum Therapeutics0.00%+7.25%-43.85%-45.35%-41.82%KALAKALA BIO0.00%+37.26%+38.85%-69.51%-98.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTNHillstream Biopharma 1.00SellN/AN/AEDITEditas Medicine 2.57Moderate Buy$5.40100.74% UpsideFULCFulcrum Therapeutics 1.75Reduce$8.20121.62% UpsideKALAKALA BIO 2.00Hold$1,018.7528,120.22% UpsideCurrent Analyst Ratings BreakdownLatest KALA, EDIT, FULC, and CNTN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026CNTNHillstream Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/3/2026CNTNHillstream Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/3/2026FULCFulcrum Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Underweight6/2/2026FULCFulcrum Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeUnderperform ➝ Underweight6/2/2026FULCFulcrum Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.006/2/2026FULCFulcrum Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$4.006/2/2026FULCFulcrum Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$3.006/2/2026FULCFulcrum Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/2/2026FULCFulcrum Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$4.006/2/2026FULCFulcrum Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$3.006/2/2026FULCFulcrum Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$3.00(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTNHillstream BiopharmaN/AN/AN/AN/A$10.92 per shareN/AEDITEditas Medicine$40.52M6.50N/AN/A$0.28 per share9.61FULCFulcrum Therapeutics$80M3.08N/AN/A$6.45 per share0.57KALAKALA BION/AN/AN/AN/A$12.56 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTNHillstream Biopharma-$35.92M-$1.15N/AN/AN/AN/A-31.50%-24.72%N/AEDITEditas Medicine-$160.06M-$1.23N/AN/AN/A-281.59%-677.39%-58.25%8/11/2026 (Estimated)FULCFulcrum Therapeutics-$74.88M-$1.15N/AN/AN/AN/A-27.80%-26.32%8/4/2026 (Estimated)KALAKALA BIO-$26.98M-$96.14N/AN/AN/AN/A-1,336.10%-94.85%8/6/2026 (Estimated)Latest KALA, EDIT, FULC, and CNTN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026KALAKALA BIO-$8.50-$0.14+$8.36-$0.14N/AN/A5/5/2026Q1 2026EDITEditas Medicine-$0.30-$0.26+$0.04-$0.26$6.37 million$2.83 million4/27/2026Q1 2026FULCFulcrum Therapeutics-$0.31-$0.25+$0.06-$0.25N/AN/A4/15/2026Q4 2025KALAKALA BIO-$8.50$0.86+$9.36$43.00N/AN/A3/31/2026Q4 2025CNTNHillstream BiopharmaN/A$0.54N/A$0.54N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTNHillstream BiopharmaN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTNHillstream BiopharmaN/A37.7637.76EDITEditas MedicineN/A3.223.22FULCFulcrum TherapeuticsN/A34.3334.33KALAKALA BION/A7.917.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTNHillstream Biopharma1.16%EDITEditas Medicine71.90%FULCFulcrum Therapeutics89.83%KALAKALA BIO24.61%Insider OwnershipCompanyInsider OwnershipCNTNHillstream Biopharma6.70%EDITEditas Medicine3.10%FULCFulcrum Therapeutics7.30%KALAKALA BIO2.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTNHillstream Biopharma269.81 million65.13 millionN/AEDITEditas Medicine23097.91 million94.87 millionOptionableFULCFulcrum Therapeutics10066.63 million61.77 millionOptionableKALAKALA BIO3018.59 million18.17 millionNot OptionableKALA, EDIT, FULC, and CNTN HeadlinesRecent News About These CompaniesKALA stock hits record low – firm announces reverse split after shares fail to surpass the $1 markMay 8, 2026 | msn.comKALA BIO Announces Reverse Stock SplitMay 7, 2026 | globenewswire.comHow smart traders spot penny stock breakouts fastMay 1, 2026 | msn.comKala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic MedicineApril 21, 2026 | globenewswire.comKala Bio Delays 2025 Annual Report FilingApril 6, 2026 | theglobeandmail.comKala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and ...April 1, 2026 | caledonianrecord.comCKala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development OpportunitiesApril 1, 2026 | globenewswire.comKALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now LiveMarch 30, 2026 | globenewswire.comEXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform LaunchMarch 30, 2026 | benzinga.comRed Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug CandidateMarch 18, 2026 | markets.businessinsider.comRed Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug CandidateMarch 18, 2026 | globenewswire.comRed Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug CandidateMarch 18, 2026 | newsfilecorp.comNAI Platforms, Data Infrastructure, and Healthcare Innovation Shape the Market NarrativeMarch 11, 2026 | markets.businessinsider.comKala Bio chases 'Palantir for biotech' dream with new AI platformMarch 11, 2026 | msn.comYounet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research AgentsMarch 11, 2026 | newsfilecorp.comNKala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution AcceleratesMarch 11, 2026 | globenewswire.comStock Trend Capital Provides Younet AI Investment UpdateMarch 9, 2026 | newsfilecorp.comNKala Bio rises on plans to leverage AIMarch 4, 2026 | seekingalpha.comKALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development ...March 4, 2026 | markets.businessinsider.comKALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”March 4, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThese 3 CLO ETFs Target a Niche Corner of the Fixed-Income MarketBy Nathan Reiff | May 31, 2026CAVA Group’s Stock Looks Delicious After Strong EarningsBy Chris Markoch | May 22, 2026Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor TestBy Jessica Mitacek | June 6, 20263 ETFs For the Coming Genomics RevolutionBy Nathan Reiff | June 7, 2026Synchrony’s Comeback Is Hiding in Plain SightBy Peter Frank | June 10, 2026KALA, EDIT, FULC, and CNTN Company DescriptionsHillstream Biopharma NASDAQ:CNTN$3.35 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.40 +0.05 (+1.49%) As of 06/18/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.Editas Medicine NASDAQ:EDIT$2.69 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$2.69 0.00 (0.00%) As of 06/18/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Fulcrum Therapeutics NASDAQ:FULC$3.70 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.70 -0.01 (-0.14%) As of 06/18/2026 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.KALA BIO NASDAQ:KALA$3.61 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.57 -0.04 (-1.00%) As of 06/18/2026 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
